ACCP-ASHP Cardiology Pharmacy Preparatory Review Course Online Book, Online Course, CE 2026 (Videos + Audios + Slides)

Cardiology Pharmacy Review 2026: ACCP-ASHP Course

Cardiology Pharmacy • BCCP Board Review • Cardiovascular Pharmacotherapy • Dyslipidemia • Hypertension • Anticoagulation • Arrhythmias • Heart Failure • ACS • Cardiovascular Emergencies • Pulmonary Hypertension

The ACCP/ASHP Cardiology Pharmacy Preparatory Review Course 2026 provides a comprehensive, case-based review of cardiovascular pharmacotherapy for pharmacists preparing for the Board of Pharmacy Specialties (BPS) Cardiology Pharmacy Specialty Certification Examination and for practitioners seeking a structured self-paced review of contemporary cardiovascular disease states and therapeutics.

Developed jointly by the American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP), the course is structured around the domains, tasks, and knowledge statements represented in the BPS Cardiology Pharmacy content outline.

The 2026 curriculum includes 7 major modules spanning the full scope of cardiology pharmacy, from cardiovascular prevention and dyslipidemia through anticoagulation, arrhythmias, chronic and decompensated heart failure, heart transplantation, mechanical circulatory support, acute coronary syndrome, cardiovascular emergencies, pulmonary arterial hypertension, infective endocarditis, pericarditis, myocarditis, evidence translation, and cardiology pharmacy practice administration.

The official course uses extensive case-based learning with more than 130 patient cases and more than 140 self-assessment questions with explained answers, allowing learners to apply cardiovascular pharmacotherapy principles to realistic clinical scenarios.

Course Details

• Course: ACCP/ASHP Cardiology Pharmacy Preparatory Review Course
• Provider: American College of Clinical Pharmacy (ACCP) / American Society of Health-System Pharmacists (ASHP)
• Year: 2026
• Release Date: June 17, 2026
• Primary Focus: Cardiology Pharmacy Board Review
• Board Focus: BPS Cardiology Pharmacy Specialty Certification / BCCP
• Official Curriculum: 7 Modules
• Official CPE: 24.5 Contact Hours
• Recertification Credit: Not Available for the 2026 Course
• ACPE Deadline: June 17, 2029
• Learning Approach: Application-Based / Case-Based
• Language: English
• MedicalAmboss Package: Videos + Audios + Slides
• Study Format: Self-Paced
• Official Study Materials: Online Workbook + Audio-Synchronized Slides + MP3 + MP4 + PDF Slides + Practice Exam

Important 2026 Credit Notice

The 2026 Cardiology Pharmacy Preparatory Review Course is available for Continuing Pharmacy Education (CPE) credit only.

BCCP recertification credit is not available with the 2026 course.

This is an important distinction from some other ACCP/ASHP specialty review programs.

The official 2026 activity provides:

• 24.5 hours of CPE
• 0 hours of BCCP recertification credit

The educational content remains designed for preparation for the Cardiology Pharmacy Specialty Certification Examination and for comprehensive cardiovascular pharmacotherapy review.

Target Audience

The course is designed primarily for pharmacists preparing for the Board of Pharmacy Specialties Cardiology Pharmacy Specialty Certification Examination.

It is also appropriate for practitioners seeking a broad review and refresher of cardiovascular disease states and therapeutics.

The course is particularly relevant to:

• Cardiology Pharmacists
• Pharmacists preparing for BCCP certification
• Clinical Pharmacists
• Cardiovascular Clinical Pharmacy Specialists
• Heart Failure Pharmacists
• Cardiac Intensive Care Pharmacists
• Anticoagulation Pharmacists
• Ambulatory Cardiology Pharmacists
• Hospital Pharmacists
• Transplant Pharmacists
• Critical Care Pharmacists involved in cardiovascular care
• Pharmacy Residents
• PGY1 Pharmacy Residents
• PGY2 Cardiology Pharmacy Residents
• Pharmacy Fellows
• Pharmacists working in heart failure programs
• Pharmacists practicing in cardiac catheterization or cardiovascular intensive care settings

Program Overview

Cardiology pharmacy requires the integration of cardiovascular pathophysiology, pharmacology, evidence-based guidelines, clinical trials, risk assessment, drug monitoring, comorbid conditions, and patient-specific treatment factors.

The ACCP/ASHP Cardiology Pharmacy Preparatory Review Course 2026 covers cardiovascular care across the entire disease spectrum.

The curriculum begins with prevention and cardiovascular risk-factor modification, then progresses through chronic atherosclerotic disease, anticoagulation, rhythm disorders, heart failure, transplantation, mechanical circulatory support, acute coronary disease, cardiovascular emergencies, pulmonary arterial hypertension, and specialized cardiovascular disorders.

The final module addresses the translation of scientific evidence into clinical practice and the administrative principles required for modern cardiology pharmacy services.

The seven official modules are:

1. Primary Prevention, Dyslipidemia, and Blood Pressure Management
2. Stable Atherosclerotic Disease and Anticoagulation
3. Arrhythmias and Drug-Induced Cardiovascular Disease
4. Chronic Heart Failure, Decompensated Heart Failure, Heart Transplant, and Mechanical Circulatory Support
5. Acute Coronary Syndrome and Cardiovascular Emergencies
6. Pulmonary Arterial Hypertension and Specialized Cardiovascular Topics
7. Translation of Evidence Into Practice and Cardiology Pharmacy Practice Administration

Official Course Modules

Module 1 – Primary Prevention of Cardiovascular Disease and Public Health; Dyslipidemia; Blood Pressure Management in Adult Patients

Official Credit: 4.75 Contact Hours

This module establishes the foundation of cardiovascular prevention and risk-factor management.

Primary Prevention of Cardiovascular Disease and Public Health

Focuses on reducing the probability of a first cardiovascular event through lifestyle modification, pharmacotherapy, tobacco cessation, and individualized risk assessment.

Major topics include:

• Cardiovascular disease prevention
• ASCVD risk assessment
• Lifestyle modification
• Tobacco cessation
• Primary prevention pharmacotherapy
• Aspirin in primary prevention
• Cardiovascular risk factors
• Preventive cardiology
• Public health strategies
• Complementary therapies
• Vitamin D
• Omega-3 fatty acids

Learners evaluate patient scenarios and design evidence-based plans to reduce cardiovascular risk.

Dyslipidemia

Reviews contemporary management of abnormal lipids and prevention of atherosclerotic cardiovascular disease.

Topics include:

• Cholesterol metabolism
• Lipoproteins
• ASCVD
• LDL cholesterol
• Statin therapy
• Statin intensity
• Nonstatin therapy
• Statin intolerance
• Hypertriglyceridemia
• Cardiovascular risk enhancers
• Pooled Cohort Equations
• Lipid monitoring
• Diabetes and lipid management
• Chronic kidney disease and lipid therapy
• Older adults and dyslipidemia

The module emphasizes selecting appropriate treatment intensity and monitoring according to patient risk.

Blood Pressure Management in Adult Patients

Reviews evidence-based antihypertensive pharmacotherapy.

Important areas include:

• Hypertension diagnosis
• Blood pressure targets
• Lifestyle modification
• Initial antihypertensive treatment
• Combination therapy
• Resistant hypertension
• Comorbid conditions
• Cardiovascular risk reduction
• Treatment monitoring
• Adverse effects
• Patient-specific drug selection

Module 1 Faculty

Carol Heunisch, Pharm.D., BCPS, BCCP

Director, Drug Policy and Education, North Region
Endeavor Health

Brandon E. Cave, Pharm.D., BCCP, AACC, AHSCP-CHC

Clinical Pharmacist Practitioner – Cardiology
West Palm Beach VA Healthcare System

Elisabeth M. Wang, Pharm.D., BCCP

Clinical Associate Professor
University of Houston College of Pharmacy

Module 2 – Stable Atherosclerotic Disease and Anticoagulation

Official Credit: 3.50 Contact Hours

This module focuses on long-term pharmacotherapy for atherosclerotic cardiovascular disease and evidence-based anticoagulation.

Stable Atherosclerotic Disease

Reviews secondary prevention and long-term management of patients with established ASCVD.

Major areas include:

• Chronic coronary disease
• Secondary prevention
• Peripheral arterial disease
• Cerebrovascular disease
• Prior myocardial infarction
• Stable ischemic heart disease
• Antiplatelet therapy
• Lipid-lowering therapy
• Blood pressure management
• Lifestyle intervention
• Cardiovascular event prevention

The emphasis is on reducing recurrent ischemic events and optimizing long-term cardiovascular outcomes.

Anticoagulation

Provides a comprehensive review of antithrombotic treatment in common cardiovascular conditions.

Topics include:

• Atrial fibrillation
• Venous thromboembolism
• Deep vein thrombosis
• Pulmonary embolism
• Mechanical heart valves
• Oral anticoagulants
• Direct oral anticoagulants
• Warfarin
• Patient selection
• Drug interactions
• Bleeding risk
• Thromboembolic risk
• Monitoring
• Therapy transitions
• Periprocedural considerations

Module 2 Faculty

Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP

Professor of Clinical Pharmacy and Translational Science
University of Tennessee College of Pharmacy

Paul P. Dobesh, Pharm.D., FCCP, FACC, FAHA, BCPS, BCCP

Professor of Pharmacy Practice and Science
University of Nebraska Medical Center College of Pharmacy

Module 3 – Arrhythmias; Drug-Induced Cardiovascular Disease and Drugs to Avoid in Cardiovascular Disease

Official Credit: 2.75 Contact Hours

Arrhythmias

Reviews pharmacologic management of atrial and ventricular rhythm disorders.

Topics include:

• Atrial fibrillation
• Atrial flutter
• Ventricular arrhythmias
• QT interval
• QTc calculation
• Antiarrhythmic drugs
• Mechanisms of antiarrhythmic agents
• Rate control
• Rhythm control
• Drug selection
• Treatment monitoring
• Transitions of care

Learners develop evidence-based pharmacotherapy plans for patients with clinically important arrhythmias.

Drug-Induced Cardiovascular Disease

Focuses on identifying medication-related cardiovascular toxicity.

Topics include:

• Drug-induced arrhythmias
• QT prolongation
• Torsades de pointes
• Drug-induced hypertension
• Drug-induced heart failure
• Cardiovascular toxicity
• Medication-associated ischemia
• Anticancer therapy cardiovascular toxicity
• Medication reconciliation
• Preventable cardiovascular adverse effects

Drugs to Avoid in Cardiovascular Disease

Examines medications that can worsen established cardiovascular disorders.

Important concepts include:

• Drugs that worsen heart failure
• QT-prolonging medications
• Drugs increasing arrhythmia risk
• Cardiovascular effects of oncology therapies
• Medication-related thrombosis
• Heparin-induced thrombocytopenia
• Risk assessment
• Alternative treatment selection

Module 3 Faculty

Zachary R. Noel, Pharm.D., Ph.D., BCCP

Associate Professor
University of North Carolina at Chapel Hill Eshelman School of Pharmacy

Richard J. Rovelli, Pharm.D., BCCP

Cardiology Clinical Pharmacy Specialist
University of Maryland Medical Center

Genevieve M. Hale, Pharm.D., BCPS, BCCP, CPh

Associate Professor
Nova Southeastern University Barry and Judy Silverman College of Pharmacy

Module 4 – Chronic Heart Failure; Decompensated Heart Failure; Heart Transplant and Mechanical Circulatory Support

Official Credit: 4.00 Contact Hours

This module provides an advanced review of heart failure pharmacotherapy from stable chronic disease through cardiogenic decompensation and advanced heart failure therapies.

Chronic Heart Failure

Reviews classification, pathophysiology, diagnosis, and evidence-based treatment of chronic heart failure.

Topics include:

• Heart failure classification
• HFrEF
• HFmrEF
• HFpEF
• Disease staging
• Neurohormonal activation
• Guideline-directed medical therapy
• Beta-blockers
• Renin-angiotensin system therapies
• ARNIs
• Mineralocorticoid receptor antagonists
• SGLT2 inhibitors
• Diuretics
• Comorbidities
• Monitoring
• Clinical trial evidence
• Readmission prevention

Decompensated Heart Failure

Focuses on acute deterioration in patients with heart failure.

Topics include:

• Hemodynamic assessment
• Pulmonary artery catheter data
• Volume overload
• Diuretic therapy
• Diuretic resistance
• IV vasodilators
• Positive inotropes
• Organ perfusion
• Congestion management
• Monitoring response
• Hospital discharge optimization
• Readmission reduction

Heart Transplant

Reviews pharmacotherapy in advanced heart failure patients undergoing heart transplantation.

Topics include:

• Heart transplant risk assessment
• Immunosuppression
• Rejection prevention
• Perioperative pharmacotherapy
• Post-transplant monitoring
• Drug interactions
• Transplant complications

Mechanical Circulatory Support

Reviews medication management in patients requiring advanced mechanical support.

Topics include:

• Left ventricular assist devices
• Durable LVAD therapy
• Mechanical circulatory support
• Thromboprophylaxis
• Anticoagulation
• Extracorporeal membrane oxygenation
• ECMO
• Pharmacotherapy during extracorporeal support
• LVAD complications

Module 4 Faculty

Theodore Berei, Pharm.D., MBA, FHFSA, BCCP

Clinical Specialist, Advanced Heart Failure and Transplant Cardiology
University of Wisconsin Hospitals and Clinics

Stormi E. Gale, Pharm.D., FHFSA, BCCP, BCPS

Clinical Pharmacy Specialist, Cardiovascular Intensive Care Unit
Atrium Health Carolinas Medical Center

Christina Ruggia-Check, Pharm.D., FAST, BCPS, BCCP, BCTXP

Clinical Pharmacy Specialist – CV Surgery/Heart Transplant
Temple University Hospital

Module 5 – Acute Coronary Syndrome and Cardiovascular Emergencies

Official Credit: 3.00 Contact Hours

Acute Coronary Syndrome

Reviews evidence-based treatment of STEMI and NSTE-ACS.

Topics include:

• STEMI
• NSTE-ACS
• Reperfusion therapy
• Primary PCI
• Antiplatelet therapy
• Anticoagulation
• Antithrombotic therapy
• Secondary prevention
• Thrombotic risk
• Bleeding risk
• Pharmacokinetics
• Drug interactions
• Post-ACS therapy
• Mortality-reducing pharmacotherapy

Learners compare reperfusion strategies and develop individualized treatment plans for acute and post-ACS care.

Cardiovascular Emergencies

Reviews pharmacotherapy for life-threatening cardiovascular presentations.

Topics include:

• Cardiac arrest
• Advanced cardiovascular life support
• Shock
• Cardiogenic shock
• Distributive shock
• Hypovolemic shock
• Obstructive shock
• Hypertensive crisis
• Acute aortic syndrome
• Acute ischemic stroke
• Emergency pharmacotherapy
• Hemodynamic support

Module 5 Faculty

Elizabeth Tien, Pharm.D., BCPS, BCCP

Clinical Pharmacy Specialist – Cardiology
UCSF Medical Center

Steven P. Dunn, Pharm.D., FCCP, FAHA, BCCP

Lead Pharmacist, Heart and Vascular
University of Virginia Health System

Module 6 – Pulmonary Arterial Hypertension and Specialized Topics in Cardiovascular Disease

Official Credit: 2.75 Contact Hours

Pulmonary Arterial Hypertension

Reviews contemporary PAH classification, pathobiology, risk assessment, and targeted therapy.

Topics include:

• Pulmonary hypertension classification
• Pulmonary arterial hypertension
• PAH pathobiology
• Treatment pathways
• Endothelin pathway
• Nitric oxide pathway
• Prostacyclin pathway
• Risk assessment
• Treatment goals
• Targeted PAH therapies
• Drug dosing
• Monitoring
• Drug interactions
• Adverse effects
• Decompensated PAH
• Combination therapy

Specialized Topics in Cardiovascular Disease

Covers additional clinically important cardiovascular disorders.

Topics include:

• Infective endocarditis
• Empiric antibiotic therapy
• Endocarditis treatment
• Endocarditis prophylaxis
• Pericarditis
• Myocarditis
• Medication selection
• Treatment monitoring
• Cardiovascular infection management

Module 6 Faculty

James C. Coons, Pharm.D., FCCP, FACC, BCCP

Professor
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology, UPMC Presbyterian Hospital

Scott Bolesta, Pharm.D., FCCP, FCCM, BCCCP

Professor of Pharmacy Practice
Wilkes University

Module 7 – Translation of Evidence into Practice and Principles of Cardiology Pharmacy Practice Administration

Official Credit: 3.75 Contact Hours

The final module focuses on turning cardiovascular research into safe, effective clinical practice while also developing and managing cardiology pharmacy services.

Translation of Evidence into Practice

Reviews how pharmacists critically evaluate cardiovascular evidence and apply it to individual patients.

Topics include:

• Evidence-based medicine
• Clinical trial interpretation
• Study design
• Cardiovascular literature evaluation
• Statistical interpretation
• Guideline interpretation
• Risk-benefit assessment
• Applying clinical evidence
• Individualizing therapy
• Clinical decision-making
• Comparative effectiveness
• Translational evidence

Principles of Cardiology Pharmacy Practice Administration

Focuses on the professional and administrative aspects of providing high-quality cardiology pharmacy services.

Topics include:

• Cardiology pharmacy practice models
• Clinical pharmacy service development
• Medication-use systems
• Quality improvement
• Patient safety
• Clinical documentation
• Interprofessional collaboration
• Outcome assessment
• Healthcare resource utilization
• Pharmacy service evaluation
• Implementation of evidence-based practice

Module 7 Faculty

William L. Baker, Pharm.D., FCCP, FACC, FHFSA

Professor of Pharmacy Practice
University of Connecticut School of Pharmacy

Ashley Schenk, Pharm.D., BCPS, BCCP, AACC

Cardiology Clinical Pharmacist
UK HealthCare

Case-Based Learning Approach

A defining feature of the ACCP/ASHP Cardiology Pharmacy Preparatory Review Course 2026 is its emphasis on application-based clinical reasoning.

The official workbook includes:

• More than 130 patient cases with explained answers
• More than 140 self-assessment questions with explained answers
• Current and relevant references
• Comprehensive cardiology pharmacy chapters
• Practice examination

Clinical cases challenge learners to integrate:

• Patient history
• Cardiovascular risk
• Electrocardiography
• Hemodynamics
• Laboratory data
• Comorbidities
• Organ function
• Current medications
• Drug interactions
• Guideline recommendations
• Clinical trial evidence
• Monitoring
• Safety
• Long-term cardiovascular outcomes

Major Topics Covered

• Cardiology Pharmacy
• BCCP Board Review
• Cardiovascular Pharmacotherapy
• Primary Cardiovascular Prevention
• Public Health
• ASCVD Risk
• Dyslipidemia
• Hypercholesterolemia
• Hypertriglyceridemia
• Statin Therapy
• Nonstatin Therapy
• Hypertension
• Blood Pressure Management
• Stable Atherosclerotic Disease
• Chronic Coronary Disease
• Peripheral Arterial Disease
• Secondary Prevention
• Anticoagulation
• Atrial Fibrillation
• Venous Thromboembolism
• Direct Oral Anticoagulants
• Warfarin
• Mechanical Heart Valves
• Arrhythmias
• Antiarrhythmic Therapy
• QT Prolongation
• Torsades de Pointes
• Drug-Induced Cardiovascular Disease
• Cardiotoxicity
• Heparin-Induced Thrombocytopenia
• Chronic Heart Failure
• HFrEF
• HFpEF
• Guideline-Directed Medical Therapy
• Decompensated Heart Failure
• Diuretic Resistance
• Inotropes
• Vasodilators
• Heart Transplant
• Immunosuppression
• Mechanical Circulatory Support
• LVAD
• ECMO
• Acute Coronary Syndrome
• STEMI
• NSTE-ACS
• PCI
• Antiplatelet Therapy
• Cardiovascular Emergencies
• Cardiac Arrest
• Shock
• Hypertensive Crisis
• Acute Aortic Syndrome
• Acute Ischemic Stroke
• Pulmonary Arterial Hypertension
• PAH Pharmacotherapy
• Infective Endocarditis
• Pericarditis
• Myocarditis
• Evidence-Based Cardiology
• Clinical Trial Interpretation
• Cardiology Pharmacy Administration
• Quality Improvement
• Medication Safety

Board Certification Preparation

The course is designed to support pharmacists preparing for the BPS Cardiology Pharmacy Specialty Certification Examination.

The curriculum is aligned with cardiology pharmacy domains, tasks, and knowledge statements and provides:

• Comprehensive cardiovascular disease-state review
• Case-based pharmacotherapy application
• Board-oriented knowledge review
• Patient-specific treatment planning
• Self-assessment questions
• Explained answers
• Clinical references
• Practice examination
• Evidence-based cardiology review
• Therapeutic monitoring principles

The practice examination can also be used as a diagnostic tool to identify weaker areas requiring additional review.

Official Continuing Pharmacy Education

The official 2026 course provides:

• 24.5 hours of Continuing Pharmacy Education (CPE)

Important dates:

• Release Date: June 17, 2026
• ACPE Deadline: June 17, 2029

The seven official module credits are:

• Module 1: 4.75 hours
• Module 2: 3.50 hours
• Module 3: 2.75 hours
• Module 4: 4.00 hours
• Module 5: 3.00 hours
• Module 6: 2.75 hours
• Module 7: 3.75 hours

Total: 24.50 CPE hours

Important Recertification Notice

The 2026 Cardiology Pharmacy Preparatory Review Course does NOT offer BCCP recertification credit.

Official CPE credit requires participation through the authorized ACCP/ASHP educational platform and successful completion of the applicable learning activities.

Course Media

The official ACCP/ASHP course includes:

• Online workbook chapters
• Audio-synchronized slide presentations
• Downloadable MP3 audio files
• Downloadable MP4 video files
• Downloadable/printable PDF presentation slides
• Practice Exam
• References and learning materials

The MedicalAmboss package includes Videos + Audios + Slides for flexible self-paced review.

Learners can:

• Watch recorded presentations
• Listen to lectures separately
• Review presentation slides
• Repeat challenging cardiovascular topics
• Organize study by module
• Combine audiovisual and written study methods
• Use the course as a structured BCCP examination review

Why This Course Is Relevant

The ACCP/ASHP Cardiology Pharmacy Preparatory Review Course 2026 provides broad coverage of cardiovascular pharmacotherapy from prevention through advanced heart failure and cardiovascular emergencies.

It is particularly valuable for pharmacists seeking education in:

• BCCP board examination preparation
• Cardiovascular risk reduction
• Dyslipidemia
• Hypertension
• ASCVD
• Anticoagulation
• Atrial fibrillation
• Arrhythmias
• Cardiotoxicity
• Heart failure
• Acute decompensated heart failure
• Heart transplantation
• LVAD management
• ECMO pharmacotherapy
• Acute coronary syndrome
• Cardiac emergencies
• Pulmonary arterial hypertension
• Infective endocarditis
• Pericarditis
• Myocarditis
• Clinical evidence interpretation
• Cardiovascular pharmacy administration

Its case-based structure helps learners bridge cardiovascular guidelines and clinical trial evidence with individualized pharmacotherapy decisions.

Short Description

ACCP/ASHP Cardiology Pharmacy Preparatory Review Course 2026 provides a comprehensive case-based review for BCCP board preparation, covering cardiovascular prevention, dyslipidemia, hypertension, ASCVD, anticoagulation, arrhythmias, heart failure, heart transplantation, mechanical circulatory support, acute coronary syndrome, cardiovascular emergencies, pulmonary arterial hypertension, endocarditis, pericarditis, myocarditis, and evidence-based cardiology pharmacy practice.

The MedicalAmboss package includes Videos + Audios + Slides for flexible self-paced review.

+ Topics:

• 01 Cardiovascular Disease Prevention – Lifestyle Modification, Risk Assessment, Tobacco Cessation, Pharmacotherapy, and Primary Prevention Strategies
• 02 Dyslipidemia Management – ASCVD Risk Assessment, Statins, Nonstatin Therapy, Hypertriglyceridemia, and Lipid Monitoring
• 03 Hypertension Pharmacotherapy – Blood Pressure Targets, Antihypertensive Selection, Combination Therapy, and Treatment Monitoring
• 04 Stable Atherosclerotic Cardiovascular Disease – Chronic Coronary Disease, Secondary Prevention, PAD, Stroke Prevention, and Long-Term Risk Reduction
• 05 Anticoagulation – Atrial Fibrillation, VTE, Mechanical Valves, DOACs, Warfarin, Bleeding Risk, and Therapeutic Monitoring
• 06 Cardiac Arrhythmias – Atrial and Ventricular Rhythm Disorders, Antiarrhythmic Drugs, QT Assessment, and Patient-Specific Pharmacotherapy
• 07 Drug-Induced Cardiovascular Disease – Cardiotoxicity, QT Prolongation, Torsades de Pointes, Oncology Therapies, and Medication-Related Cardiovascular Risk
• 08 Chronic Heart Failure – HFrEF, HFpEF, Guideline-Directed Medical Therapy, Comorbidity Management, and Evidence-Based Treatment
• 09 Acute Decompensated Heart Failure – Hemodynamic Assessment, Diuretics, Diuretic Resistance, Vasodilators, Inotropes, and Readmission Prevention
• 10 Heart Transplant Pharmacotherapy – Immunosuppression, Rejection Prevention, Drug Interactions, and Post-Transplant Medication Management
• 11 Mechanical Circulatory Support – LVAD, ECMO, Anticoagulation, Thromboprophylaxis, and Pharmacotherapy During Advanced Cardiac Support
• 12 Acute Coronary Syndrome – STEMI, NSTE-ACS, PCI, Antiplatelet Therapy, Anticoagulation, Reperfusion, and Secondary Prevention
• 13 Cardiac Arrest and Cardiovascular Emergencies – Resuscitation Pharmacotherapy, Shock Management, and Acute Hemodynamic Support
• 14 Hypertensive Crisis – Emergency Blood Pressure Reduction, Drug Selection, Monitoring, and Organ-Specific Treatment Strategies
• 15 Acute Aortic Syndrome – Emergency Cardiovascular Pharmacotherapy, Hemodynamic Control, and Treatment Planning
• 16 Acute Ischemic Stroke – Cardiovascular Pharmacotherapy Considerations and Evidence-Based Acute Treatment Planning
• 17 Pulmonary Arterial Hypertension – Classification, Risk Assessment, Targeted Therapy, Combination Treatment, and Decompensated PAH
• 18 Infective Endocarditis – Empiric Therapy, Definitive Treatment, Prophylaxis, and Cardiovascular Infection Management
• 19 Pericarditis – Evidence-Based Anti-Inflammatory Pharmacotherapy, Recurrence Prevention, and Treatment Monitoring
• 20 Myocarditis – Clinical Assessment, Supportive Pharmacotherapy, and Cardiovascular Management
• 21 Cardiovascular Clinical Trial Interpretation – Applying Study Design, Risk Estimates, and Contemporary Evidence to Patient Care
• 22 Translation of Evidence Into Practice – Integrating Guidelines, Trials, and Patient-Specific Factors Into Cardiovascular Pharmacotherapy
• 23 Cardiology Pharmacy Administration – Clinical Service Development, Documentation, Quality Improvement, and Interprofessional Practice
• 24 Cardiovascular Medication Safety – Drug Interactions, Adverse Effects, Monitoring, Cardiotoxicity, and High-Risk Pharmacotherapy
• 25 BCCP Board Examination Preparation – Case-Based Cardiovascular Clinical Reasoning, Self-Assessment, Practice Questions, and Specialty Review